See January's 10 most read stories, including the impact of the novel coronavirus COVID-19 on nutrition businesses, Singapore's lab-grown breast milk innovation and more. Click through the gallery to see them all.
India’s Ministry of AYUSH has attracted criticism from medical experts for suggesting alternative medicines, such as Ayurveda, homoeopathy, and unani practices, could act as immunity booster against the deadly novel coronavirus.
A number of Chinese health food firms have seen an increase in demand for products related to immunity boosting and respiratory health amid the Wuhan virus outbreak.
The ongoing China Coronavirus outbreak has affected a number of nutrition retailers which rely on Chinese tourists as a key revenue stream, with some putting on hold new plans and adopting a ‘wait and see’ approach.
A Singapore start-up is aiming to launch lab-grown breast milk by 2021, and is seeking to work with major formula brands to deliver the “closest thing to real mothers’ breast milk”.
Four of GNC’s health supplements have obtained the ‘blue-hat’ status in China and can now be sold in Chinese pharmacies.
Supplement manufacturers and suppliers in China sought return to normalcy as they resume operations as the extended Chinese New Year holiday – lengthened by the novel coronavirus outbreak – comes to an end.
The Chinese authorities are conducting a public consultation for the new food safety standards that it has drafted for a number of food items, including liquid infant formula, infant formula powder, and infant food.
Several health and nutrition firms are showing their support for China’s fight against the deadly novel coronavirus in the form of cash, protective outfits, and nutrition products.
A study in the Philippines showed that children consuming milk catered to their age, such as toddler and infant formula, have higher intake of micronutrients including iron, zinc, vitamin B6, C, D, and E, as compared to those drinking other types of milk.
Evolve BioSystems, the US-based microbiome firm supported by big name investors Bill Gates and Li Ka Shing, will soon embark on local research in the APAC region, namely Singapore and Hong Kong.
